tapebrief
IFF · Q3 2025
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

IFF · Q4 2025 Earnings

International Flavors & Fragrances

Reported February 11, 2026

30-second summary

Q4 CN sales grew 1% and FY25 finished at $10.89B revenue / 19.2% EBITDA margin — at the high end of the revenue guide and mid-range on EBITDA — but the FY26 guide tells the real story: reported revenue $10.5-10.8B (-1% to -4% YoY) and CN EBITDA growth of just 3-8%, a ~100bps midpoint deceleration (6.5% → 5.5%) from the range guided all of 2025. Comparable currency-neutral sales growth of 1-4% looks unchanged on the surface, but a -5% divestiture headwind drags reported growth deeply negative, and Q1 FY26 is qualitatively flagged as "modest" EBITDA growth versus a $505M base. Food Ingredients sale remains undecided — management explicitly walked back urgency ("under no pressure to sell") — and the FY26 FCF target was deliberately withheld pending that process.

Headline numbers

EPS

Q4 FY2025

$0.80

Revenue

Q4 FY2025

$2.59B

-6.6% YoY

Gross margin

Q4 FY2025

34.4%

Operating margin

Q4 FY2025

3.7%

Key financials

Q4 FY2025
MetricQ4 FY2025YoYQ3 FY2025QoQ
Revenue$2.59B-6.6%$2.69B-3.9%
EPS$0.80—$1.05-23.8%
Gross margin34.4%—36.5%-210bps
Operating margin3.7%—8.4%-470bps

Guidance

Company delivered FY2025 results in-line with guidance but dramatically lowered FY2026 outlook, guiding to revenue decline of 1–4% and EBITDA growth of only 3–8% (versus 5–10% for FY2025), despite comparable currency neutral sales guidance holding steady at 1–4%.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
RevenueFY2025$10.6 billion to $10.9 billion$10.89 billionat the high end of guideMet
Adjusted Operating EBITDAFY2025$2.0 billion to $2.15 billion$2.086 billionwithin guide, mid-rangeMet

New guidance

MetricPeriodGuideYoY
Adjusted Operating EBITDAFY2026$2.05 billion to $2.15 billion-1% to +3% YoY
RevenueFY2026$10.5 billion to $10.8 billion-4% to -1% YoY
Comparable Currency Neutral Sales GrowthFY20261% to 4%—
Comparable Currency Neutral Adjusted Operating EBITDA GrowthFY20263% to 8%—
Adjusted Operating EBITDAQ1 FY2026Modest growth versus like-for-like Q1 2025 base of approximately $505 million—

Segment KPIs

Q4 FY2025
SegmentQ4 FY2025YoY
Taste$0.588B+2.6%
Health & Biosciences$0.589B+7.1%
Scent$0.61B+5.5%
Food Ingredients$0.802B-2.1%
Taste (FY2025)$2.481B+2.5%
Health & Biosciences (FY2025)$2.283B+3.6%
Scent (FY2025)$2.479B+2.8%
Food Ingredients (FY2025)$3.278B-2.6%

Other KPIs

Q4 FY2025
SegmentQ4 FY2025
Adjusted Operating EBITDA Margin (Q4)16.9%
Adjusted Operating EBITDA Margin (FY2025)19.2%
Taste Adjusted Operating EBITDA Margin16.0%
Health & Biosciences Adjusted Operating EBITDA Margin26.3%
Scent Adjusted Operating EBITDA Margin17.4%
Food Ingredients Adjusted Operating EBITDA Margin10.2%
Net Debt to Credit Adjusted EBITDA2.6x
Free Cash Flow Margin (FY2025)2.4%

Management tone

Q1 acceleration thesis → Q2 innovation payoff deferred to 2026-2027 → Q3 Q4-flagged-as-challenge with execution-only narrative → Q4 portfolio optimization and cash flow discipline replacing growth ambition.

The Food Ingredients sale narrative has materially softened — and that is the most consequential tone shift of the quarter. Through Q2 and Q3 management telegraphed "absolute clarity in 2026" and "significant interest" from PE and strategic buyers, framing the process as on rails with February as the catalyst event. This quarter the anchor language is "we are under no pressure to sell. The business has a strong operating plan, and we are confident we can continue to create value whether a transaction occurs or not." That is a fundamental reframing — from "process underway" to "optionality." Either the bids came in below the value framework management had internalized, or the process is meaningfully slower than the Q2 "absolute clarity in 2026" line implied. Six months ago this was the binary catalyst; today it is conditional.

The growth engine has been rewritten from pricing to volume — a structural concession the prior briefs did not flag. In 2025, pricing was a contributor across Food Ingredients and parts of Scent. The FY26 framing from Erik Fyrwald: "our expected growth for 2026 is volume driven... CPG companies shifting emphasis to more volume growth, that is a good thing for IFF and the industry." Combined with explicit guidance that "pricing to be slightly down" in fragrance ingredients and "residual carryover pricing impact in food ingredients," management is conceding the pricing lever is exhausted. The bull read is volume leverage on fixed cost (incremental margins on volume cited at 30-35%). The bear read is that pricing exhaustion compresses incremental margins precisely when EBITDA growth has already been guided down at the midpoint.

Cash flow has been promoted to co-equal with growth and profit — and the FCF target has been pulled. Q2 and Q3 referenced a "$500M FCF target" management would land "modestly below." FY25 closed at $256M FCF (2.4% margin) — roughly half the prior reference point. This quarter management said "we will be laser focused in 2026 on driving profitable growth, cash flow improvement, and maximizing value creation" and introduced a FCF conversion incentive metric for 2026 — but explicitly declined to give a dollar target, citing Food Ingredients sale uncertainty. Two things are happening simultaneously: cash flow is being elevated as a priority, AND management is removing the most-watched number. That combination is a hedge.

Health & Biosciences has flipped from defensive posture to proactive turnaround narrative — and the Q4 print backs it. Last quarter's framing of new leadership with H2 2026 / 2027 recovery has been replaced by: "Leticia has brought in new leadership. The team is strong. We believe in the business... you will see the results come... we've got our eye back on the ball." The +7% reported (+5% CN) Q4 growth and 26.3% margin make this the single most credible tone improvement in the print — the only segment where evidence and rhetoric are aligned positively.

Hedging language density remains elevated despite the more confident segment commentary. "Cautiously optimistic," "we expect to deliver... growth, margin improvement, and cash flow generation," "subject to current market conditions," "more muted in the first quarter," "ranges we are providing." The cumulative weight signals that even the lowered FY26 guide is being framed as conditional. Q1 FY26 EBITDA was guided as "modest growth" against a $505M base — the lowest-resolution forward EBITDA framing in the prior-brief sequence.

Recurring themes management leaned on this quarter:

Portfolio optimization via targeted divestitures (Pharma Solutions, Nitrocellulose, Rene Laurent, planned food ingredients sale)Innovation-driven growth funded by productivity gains (emphasized $100M R&D investment, biotech/enzyme capacity expansion)GLP-1 tailwind positioning (taste, food biosciences capitalizing on reformulation demand)Cash flow prioritization and working capital discipline (introduced FCF conversion incentive metric for 2026)Health & biosciences turnaround with new leadership (Leticia Goncalves driving improvement plan)Incremental margin management via volume leverage and selective reinvestment

Risks management surfaced:

Macroeconomic uncertainty persisting through 2026 and volatile geopolitical landscapeDestocking risk at reasonable levels in end marketsFood ingredients sale execution risk and timing uncertaintyCommodity ingredient margin pressure in fragrance requiring migration to higher-value specialties (noted as 2026 theme)Input cost inflation (tariffs, raw materials, logistics, energy, packaging) requiring offsetting via pricing/reformulation/productivity

Answers to last quarter's watch list

Q4 FY2025 CN sales growth vs. the 6% PY comp — CN sales grew +1% in Q4, positive against a strong 6% prior-year comparable. FY25 revenue landed at $10.89B, at the high end of the $10.6-10.9B guide. The all-year reaffirmation held.
Resolved positively
Food Ingredients strategic alternatives at the February Q4 call — No defined process announced. Management explicitly walked back urgency with the "under no pressure to sell" framing and confirmed only that the business operates with a "strong operating plan." No sale-vs-spin decision, no value framework, no timeline. After 6+ months of "significant interest" commentary, the absence of a defined process is the negative signal Q3's watch flagged.
Resolved negatively
Initial 2026 guide framing — can EBITDA growth exceed revenue growth in a 1-2% growth environment — Yes, technically: comparable CN EBITDA growth of 3-8% exceeds CN sales growth of 1-4%. But the comparable EBITDA midpoint moved from ~6.5% to ~5.5%, and reported FY26 revenue declines 1-4% with reported EBITDA roughly flat. The -5% divestiture headwind framework bridges the lapping of divested businesses. The defensive playbook materialized as ~100bps of midpoint EBITDA growth deceleration.
Resolved negatively
FCF generation in Q4 and the $500M target gap — FY25 FCF landed at $256M (2.4% margin), well below the $500M reference point management used through 2025. Management pulled the FY26 FCF dollar target entirely, citing Food Ingredients sale uncertainty, and instead committed only to "operating cash flow will be a key priority." The gap was confirmed materially wider than "modestly below," and the forward target was withheld.
Resolved negatively
Health North America — H&B delivered +7% reported (+5% CN) Q4 revenue growth and 26.3% EBITDA margin, the strongest Q4 print of the four segments. Management's turnaround narrative under Leticia Goncalves is now anchored to actual numbers rather than a 2027 promise. This is the cleanest positive in the quarter.
Resolved positively

What to watch into next quarter

Whether the FY26 comparable CN EBITDA growth of 3-8% holds through Q1 reporting — Q1 was qualitatively guided as "modest growth" against a $505M PY base, which implies low-single-digit (2-5%) EBITDA growth. Anything below 3% in Q1 would force the FY guide toward the low end on the opening quarter — a repeat of the 2025 "low end of range" walk that started last year's defensive pivot.

Food Ingredients sale — does a defined process emerge by mid-2026, or does the "no pressure to sell" framing harden into a permanent operating posture? The Q2/Q3 "absolute clarity in 2026" commitment has now slipped; watch whether management offers any new timeline on the Q1 call or whether the optionality language persists.

FY26 FCF tracking against an unstated target — FY25 closed at $256M, half the $500M reference. With no forward target disclosed, the H1 FCF number becomes the implicit yardstick. Watch whether management reintroduces a dollar target once the Food Ingredients process resolves.

Pricing trajectory in fragrance ingredients and food ingredients — management guided pricing slightly down for 2026. Watch whether the H1 print shows pricing erosion accelerating beyond "slight," which would compress margins on the volume-driven growth thesis.

H&B sustaining the +7% reported / +5% CN Q4 trajectory — the segment delivered the strongest evidence of turnaround in the print, but a single quarter is not a trend. Q1 H&B growth above 5% CN would confirm; deceleration back to the +2-3% range seen in Q2-Q3 would suggest the Q4 print was timing.

Net leverage direction — 2.6x exiting 2025 vs. 3.8x at YE2024 is a material improvement; watch whether weaker FCF combined with reported revenue decline and potential share repurchase activity pressures the ratio higher through 2026.

Sources

  1. IFF Q4 FY2025 Press Release — https://www.sec.gov/Archives/edgar/data/51253/000005125326000003/q42025991pressreleaseofiff.htm
  2. IFF Q4 FY2025 Earnings Call Transcript (February 12, 2026)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.